Published online before print August 22, 2002, doi: 10.1161/01.ATV.0000034706.24149.95
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2002 American Heart Association, Inc.
Brief Reviews |
Antioxidant Vitamins and Lipid Therapy
End of a Long Romance?
From the Department of Medicine, Divisions of Cardiology (B.G.B., A.C.L., X.-Q.Z.) and Metabolism, Endocrinology, and Nutrition (M.C.C., A.C.), University of Washington School of Medicine, Seattle.
Correspondence to B. Greg Brown, MD, PhD, Cardiology, Box 356422, Health Sciences Building, Room A509, 1959 NE Pacific St, Seattle, WA 98195. E-mail bgbrown{at}u.washington.edu
 |
Abstract |
|---|
 Top Abstract The RomanceThe Dream FadesAnd Now, IncompatibilityWith Hindsight, It Was...Who Was to Blame?Our Relationship Was Just...In the End, the...Can We Still be...References |
|---|
During the past decade, the perception flourished that lipid and antioxidant therapy were 2 independent avenues for cardiovascular protection. However, studies have shown that commonly used antioxidant vitamin regimens do not prevent cardiovascular events. We found that the addition of antioxidant vitamins to simvastatin-niacin therapy substantially blunts the expected rise in the protective high density lipoprotein (HDL)2 cholesterol and lipoprotein(A-I) subfractions of HDL, with apparent adverse effects on the progression of coronary artery disease. To better understand this effect, 12 apolipoproteins, receptors, or enzymes that contribute to reverse cholesterol transport have been examined in terms of their relationship to HDL2 and lipoprotein(A-I) levels and the potential for antioxidant modulation of their gene expression. Three plausible candidate mechanisms are identified: (1) antioxidant stimulation of cholesteryl ester transfer protein expression/activity, (2) antioxidant suppression of macrophage ATP binding cassette transmembrane transporter A1 expression, and/or (3) antioxidant suppression of hepatic or intestinal apolipoprotein A-I synthesis or increase in apolipoprotein A-I catabolism. In summary, antioxidant vitamins E and C and ß-carotene, alone or in combination, do not protect against cardiovascular disease. Their use for this purpose may create a diversion away from proven therapies. Because these vitamins blunt the protective HDL2 cholesterol response to HDL cholesterol–targeted therapy, they are potentially harmful in this setting. We conclude that they should rarely, if ever, be recommended for cardiovascular protection.
Key Words: antioxidant vitamins • lipid therapy • atherosclerosis
|
The Romance |
|---|
|
TopAbstractThe RomanceThe Dream FadesAnd Now, IncompatibilityWith Hindsight, It Was...Who Was to Blame?Our Relationship Was Just...In the End, the...Can We Still be...References |
|---|
Over the past 15 years epidemiological,1,2 basic biological,3–5 and experimental atherosclerosis6–8 studies have supported the idea that antioxidants can protect against atherosclerosis by limiting LDL oxidation and, thus, the macrophage scavenger receptor (SR)-mediated accumulation of cholesteryl ester (CE) in the lipid-rich necrotic center of the plaque. Increased foam cell density9 and inflammatory activity10,11 and large core lipid size9 (but not stenosis severity12,13) have been identified as high-risk plaque characteristics. Although other mechanisms for plaque lipid accumulation have been described,14 oxidized LDL has provided an attractive hypothetical therapeutic target.15
In the same time period, clinical trials have found substantial risk reduction by pharmacological lowering of LDL cholesterol (LDL-C).16,17 The perception flourished that lipid lowering and antioxidant therapy were 2 independent avenues for cardiovascular protection. Many medical practitioners and the public accepted, without full proof, the promise of efficacy of this "natural" combination of preventive strategies. Other leaders in this area have adopted the more skeptical posture, ie, waiting for the prospective clinical trials.18,19
|
The Dream Fades |
|---|
|
TopAbstractThe RomanceThe Dream FadesAnd Now, IncompatibilityWith Hindsight, It Was...Who Was to Blame?Our Relationship Was Just...In the End, the...Can We Still be...References |
|---|
The antioxidant hypothesis spawned a number of large clinical trials whose results were reported between 1994 and 2000.20–24 The conclusions of these studies, briefly summarized (Table 1), are as follows: (1) There is little or no cardiovascular benefit from vitamin E in the dose ranges studied. (2) There is no cardiovascular benefit from ß-carotene. (3) There is no cancer benefit from vitamin E, and at least in smokers over the short term, new cancer risk may increase with ß-carotene.
|
Given this battering of a beautiful hypothesis with compelling negative data, a variety of explanations have been offered.25 Despite the data, physicians and the public have continued widespread antioxidant use. Part of the reasoning is that "at least it won’t hurt me."
|
And Now, Incompatibility |
|---|
|
TopAbstractThe RomanceThe Dream FadesAnd Now, IncompatibilityWith Hindsight, It Was...Who Was to Blame?Our Relationship Was Just...In the End, the...Can We Still be...References |
|---|
Attracted to the hypothetical promise of the marriage of lipid therapy and antioxidant vitamins, we randomized 160 patients with coronary artery disease (CAD) and low HDL into a factorial design angiographic trial to treatment with simvastatin plus niacin or an antioxidant cocktail (vitamins E and C, ß-carotene, and selenium) or to treatment with the full combination or their placebos.26 The results are as follows27,28: (1) Niacin and simvastatin lowered LDL-C, on average, by 42%, raised HDL2 cholesterol (HDL2-C) by 65% and Lp(A-I) by 76% (see Table 2). (2) When antioxidants were added to lipid therapy, HDL2-C rose by only 28%, and Lp(A-I) rose by 29% (Table 2); antioxidants alone lowered HDL2-C by 15% (P=0.05). (3) Simvastatin plus niacin, alone, promoted regression of coronary disease, a marker of plaque lipid depletion,29 but when antioxidants were added to lipid therapy, the disease instead progressed, although the progression was significantly slower than that with all-placebo treatment. There was a significant adverse interaction between lipid and antioxidant therapy for this primary study end point. (4) Antioxidants alone resulted in a modest nonsignificant slowing of stenosis progression relative to placebo. (5) The frequency of a first major cardiovascular event was 24% for the all-placebo group, 3% for the group receiving only simvastatin plus niacin, 21% for the group receiving only antioxidants, and 14% for the group receiving the full combination.
|
We proposed that the diminished clinical benefits in the full combination were due to the adverse effect of antioxidants on the HDL2-C and Lp(A-I) response to lipid therapy.27,28 Thus, these results, if confirmed, suggest that a combination of antioxidant vitamins can be harmful in a patient taking lipid therapy targeted at raising HDL2-C.
|
With Hindsight, It Was Predictable |
|---|
|
TopAbstractThe RomanceThe Dream FadesAnd Now, IncompatibilityWith Hindsight, It Was...Who Was to Blame?Our Relationship Was Just...In the End, the...Can We Still be...References |
|---|
Probucol is a much more potent antioxidant than our vitamin cocktail. In the Probucol Quantitative Regression Swedish Trial (PQRST),30,31 all subjects had femoral atherosclerosis, received cholestyramine, and were randomized to probucol or its placebo. In the comparison of these 2 treatment groups, probucol lowered the relative level of the large buoyant HDL2b (those particles in the 9.7- to 12.9-nm size range) by 53% and the protein concentration (mainly apoA-I) of HDL2b by 67%. The increase in mean femoral artery obstruction over 3 years was significantly correlated with reduction in HDL2b protein (r=0.44, P<0.001) and the relative HDL2b-C value (r=0.51, P<0.001). In-treatment reduction of HDL2b-C had a highly significant correlation with plasma probucol concentration. In conclusion, there was a causal and biologically meaningful link between decrease in HDL2b and femoral atherosclerosis progression. Thus, a potent nonvitamin antioxidant caused a striking HDL2-C reduction and resulting atherosclerosis progression.
An early report32 described reduction of HDL-C (-5%, P<0.05) and HDL2-C (-30%, P<0.01) but not HDL3 during diet-controlled treatment of acne vulgaris with isotretinoin (13-cis-RA, where RA indicates retinoic acid).
Atorvastatin, the metabolites of which are proven antioxidants at high concentration in vitro,33 causes a dose-dependent blunting of the HDL-C and apoA-I response relative to that seen with other statins.34 Although it is premature to attribute the blunting by atorvastatin of its HDL response to an antioxidant mechanism, it is a plausible hypothesis.
|
Who Was to Blame? |
|---|
|
TopAbstractThe RomanceThe Dream FadesAnd Now, IncompatibilityWith Hindsight, It Was...Who Was to Blame?Our Relationship Was Just...In the End, the...Can We Still be...References |
|---|
To further examine the HDL-2 blunting effects of our antioxidant cocktail (see Table 2), we conducted a vitamin substudy for a 5-month period in patients completing the original HDL Atherosclerosis Treatment Study (HATS).28 Forty-four such patients were given 10 mg simvastatin plus 2.5 g niacin daily for 3 months and were simultaneously randomly assigned to 1 of 6 antioxidant options: (1) 800 IU vitamin E plus 1000 mg vitamin C daily, (2) 25 mg ß-carotene daily, (3) 50 000 IU vitamin A daily, (4) 100 µg selenium daily, (5) the original vitamin cocktail, and (6) the original placebo. Samples were obtained at baseline and after 3 months on these combinations. The results, briefly, are as follows35: (1) The original observations on HDL-C and HDL2-C were reproduced in the substudy. (2) Three individual vitamin therapies (vitamin A, vitamins E plus C, and ß-carotene) were, on their own, as effective as the full cocktail in blunting the HDL2-C response to lipid therapy. (3) Selenium, by comparison, significantly enhanced the HDL2-C response to lipid therapy.
In that small study,35 which requires confirmation, each of the vitamins comparably blunted the HDL2-C response to lipid therapy, implying a general antioxidant effect rather than a specific culprit.
|
Our Relationship Was Just Too Complicated |
|---|
|
TopAbstractThe RomanceThe Dream FadesAnd Now, IncompatibilityWith Hindsight, It Was...Who Was to Blame?Our Relationship Was Just...In the End, the...Can We Still be...References |
|---|
A growing understanding of metabolic pathways determining HDL-C and HDL2-C levels and reverse cholesterol transport36 may help generate testable hypotheses to explain these observations. Points of potential antioxidant influence (Figure 1) include the modulation of genes expressing the ATP binding cassette (ABC) transmembrane transporter A1 (ABCA1), apoA-I, lecithin-cholesterol acyltransferase (LCAT), hepatic lipase (HL), lipoprotein lipase (LPL), endothelial lipase (EL), CE transfer protein (CETP), phospholipid (PL) transfer protein (PLTP), SR class B type I (SR-BI), and 7
-hydroxylase. Our focus in the present review is drawn to the metabolic steps that regulate the HDL2-C or Lp(A-I) particle levels.
|
Lipid-poor HDL of liver37 or intestinal38 origin acquires unesterified cholesterol and PL from sources including the ABCA1 transporter of the intimal macrophage (Figure 1). Only a small fraction of the cholesterol transported to the liver is derived from this cell type, but the ABCA1 pathway is its principal route of cholesterol efflux. These HDL particles mature under the influence of LCAT, PLTP, CETP, HL, and LPL into a steady-state collection of HDL particles of varying size, lipid, and apolipoprotein composition (Figure 2). Mature HDL particles dock on the hepatic SR-BI receptors, which selectively remove CE for intracellular cholesterol trafficking and bile production, and return lipid-poor apoA-I particles to the plasma for recycling or renal catabolism. In the following paragraphs, we examine the actions and regulation of these gene products.
|
ABCA1 Transporter
ABCA1, the mutations of which cause Tangier disease, is a 254-kDa transmembrane protein mediating cellular efflux of unesterified cholesterol, PL, and -tocopherol via HDL-linked pathways.39–45 Transgenic mice overexpressing ABCA1 have increased HDL and biliary cholesterol excretion.46 Expression of this gene is regulated by activated liver X receptor (LXR)/retinoid X receptor (RXR) nuclear heterodimers that bind to the DR4 element in its promoter region.47 Two known physiological ligands for these nuclear receptors are 9-cis-RA (for RXR)47,48 and 27-hydroxycholesterol (for LXR), which is produced by the action of 7-hydroxylase on microsomal cholesterol.49,50 Because RA and oxysterols are involved in ABCA1 expression and because -tocopherol is a secreted ligand, one role of this gene may be to regulate the level of intracellular oxidative stress. If so, antioxidant vitamins entering the cell on internalized oxidized LDL51 may downregulate the gene by interfering directly with LXR or RXR activation or via the zinc finger protein 202,52,53 resulting in reduced cholesterol efflux.
Apolipoprotein A-I
Overall, apoA-I, a 28.3-kDa amphipathic protein, accounts for 
70% of the protein in HDL. ApoA-I, apoA-II, and apoA-IV are synthesized in the liver and intestine (see Lipoproteins in Health and Disease,54 chapter 5). Lp(A-I)s, the HDL particles containing apoA-I but not apoA-II, begin as small nascent HDL disks and lipid-poor spheres37,55,56 and acquire cholesterol, PL, and apolipoproteins from other lipoproteins and from cells57 (Figure 1). They mature (Figure 2) to become the large, more buoyant HDL2b subpopulation associated with reduced atherosclerosis risk. Lp(A-I)s carry approximately one third of the HDL-C in healthy normal individuals and less than half of that in many patients with coronary disease.
Intravenous, drug-induced, or transgenic increases in apoA-I plasma levels are correlated with increased HDL-C28,58–60 (in HATS,28 r=0.63, P=0.0001) and with decreased atherosclerosis. ApoA-I has a structural domain that conveys protection against murine atherosclerosis that is independent of its levels.61 A deficiency of apoA-I and apoC-III synthesis results in the virtual absence of HDL-C and accelerated atherosclerosis.62,63 Conversely, rapid apoA-I and apoA-II turnover results in low HDL-C but may protect against atherosclerosis,64 highlighting the controversy over whether HDL levels or turnover are most protective. In vivo, thyroid hormone may reduce,65 and estrogen may increase,66–68 apoA-I synthesis and plasma levels. Niacin is thought to raise apoA-I levels by specifically slowing the catabolism of Lp(A-I).69
The promoter region of the apoA-I gene contains elements that respond to nuclear receptors whose activation regulates transcription of the apoA-I message.70,71 These include the antioxidant response element (ARE) and peroxisomal proliferator response element.72,73 ARE is capable of upregulating antioxidant defense genes when it is bound by a nuclear receptor activated by increased oxidative stress.72 A free radical–induced novel nuclear receptor(s) has been shown to bind to ARE, inducing a 2-fold increase in apoA-I gene transcription.72 Nuclear receptors include apoA-I regulatory protein (ARP)-1, RXR, retinoic acid receptor (RAR), and peroxisome proliferator–activated receptor (PPAR). ARP-1,74,75 a member of the thyroid-steroid–responsive nuclear receptor superfamily, is a nuclear receptor that suppresses apoA-I gene expression. The RXR nuclear receptors, activated by 9-cis-RA (and less so by all-trans-RA)76 stimulate apoA-I expression. PPAR activators such as fibric acids increase HDL by increasing expression of apoA-I and apoA-II genes.77,78
Apolipoprotein A-II
Little is known regarding the functions of apoA-II, a 17.4-kDa major HDL structural protein. A polymorphism in the promoter region of the apoA-II gene influences apoA-II production, visceral fat accumulation, and postprandial metabolism of large VLDLs.79 Unlike Lp(A-I), Lp(A-I, A-II) appears to promote atherosclerosis in susceptible mice,80 although this is controversial.81 In general, plasma apoA-II is thought to be proatherogenic.82 Because apoA-II and Lp(A-I, A-II) levels do not appear to be affected by simvastatin-niacin or by antioxidants (Table 2), these are not discussed further in the present review.
Lecithin-Cholesterol Acyltransferase
LCAT (see Lipoproteins in Health and Disease,54 chapter 14) is a 63-kDa glycoprotein enzyme expressed and secreted by the liver into plasma, where it is transported principally bound to HDL particles.83,84 LCAT esterifies nearly three fourths of all plasma cholesterol and also catalyzes acylation of lysophosphatidylcholine. LCAT is activated principally by apoA-I but to a lesser extent by other HDL-bound apolipoproteins (apoC-1, apoD, apoA-IV, and apoE). Predictably, increased LCAT activity would increase HDL CE content, particle size, and HDL2-C levels. LCAT transgenic rabbits show a marked decrease in aortic atherosclerosis,85 although the converse is true for similarly transgenic mice.86 Unesterified cholesterol (UC) is esterified by LCAT in HDL2 and in HDL3, the much-preferred substrate. Regulation of hepatic transcription of the LCAT gene and regulation of LCAT activity are not well understood.87 However, vitamin E does not appear to affect human LCAT activity.88
CE Transfer Protein
CETP, a 66- to 74-kDa hydrophobic glycoprotein, is expressed in liver, spleen, adipose tissue, kidney, and skeletal muscle (see Lipoproteins in Health and Disease,54 chapter 15). Its principal function is to exchange triglycerides (TGs) from apoB-containing particles for CE from HDL particles. CETP is localized principally on the larger Lp(A-I) particles.83,89
Increased expression, or activity, of CETP would predictably reduce HDL-C levels and particle size. However, the effects of variation in CETP activity remain controversial.90 Experimentally, atherosclerosis is increased in cholesterol-fed mice lacking apoE and LDL receptor (LDLR) genes and overexpressing human CETP91 and is reduced in naturally CETP-deficient mice of this type. However, Japanese patients genetically deficient in CETP are felt to have an increased incidence of atherosclerosis.92
A common CETP intron gene polymorphism, B1/B1, is in linkage disequilibrium with a polymorphism in its promoter. It is found in 36% of patients with CAD and has 30% greater plasma CETP concentration, 13% lower HDL levels, and 3 times more rapid coronary luminal narrowing than its homozygous B2/B2 counterpart (16% of patients).93 Probucol, a powerful antioxidant drug, increases CETP activity.94,95 It has been shown to lower HDL2b by 53% and its apoA-I protein level by 67%, changes that are correlated with worsening femoral arterial obstruction,31 suggesting that increased CETP activity is atherogenic. However, genetically increased CETP has tended to be protective and reduced CETP has tended to be atherogenic in 2 populations at low cardiovascular risk (low LDL-C and high HDL-C) and with low prevalence of CAD.96,97 These apparently conflicting findings would be reconciled if CETP activity is either protective or harmful depending on the atherogenicity (remnants, apoC-III or apoE4 content, and size) of the apoB particles receiving the CE from HDL.98 As Figure 1 suggests, apoB particles that return to the liver contribute to reverse cholesterol transport; those preferred by the macrophage contribute to atherogenesis.
Regulation of CETP transcription is by the same LXR/RXR nuclear receptor heterodimer that activates transcription of ABCA1.99 Similarly, ARP-1 has been shown to upregulate CETP gene transcription.74
Thus, a plausible candidate mechanism for the antioxidant vitamin–associated blunting of the favorable effects of lipid therapy on HDL2-C27 and coronary disease28 would be an antioxidant-mediated induction of CETP activity, as has been shown for probucol94,95 and vitamin E.100
PL Transfer Protein
PLTP facilitates transfer of the surface lipids (PL and unesterified cholesterol) from the apoB-containing lipoproteins onto HDL.101,102 PLTP also directly mediates PL transfer among HDL particles, thus promoting HDL size heterogeneity.103 The PLTP-mediated conversion of HDL into larger and smaller particles is thought to involve displacement from the lipoprotein surface of small lipid-poor apoA-I–containing particles, causing parent particle instability with resulting fusion into larger HDL.104 This effect applies to Lp(A-I) and Lp(A-I, A-II) HDL particles.105 PLTP activity is strongly correlated with Lp(A-I) plasma concentration but not Lp(A-I, A-II) plasma concentration.106 However, PTLP activity is not increased by lipid therapy (niacin plus simvastatin), which substantially increases Lp(A-I) concentration,107 suggesting that the rise in Lp(A-I) is not mediated directly by PLTP. By extension, the antioxidant vitamin–mediated blunting of Lp(A-I) would not be related to PLTP.
HL/LPL/EL
HLs, LPLs, ELs, and pancreatic lipases (see Lipoproteins in Health and Disease,54 chapter 12) are members of a gene family involved in processing 150 g dietary triglyceride daily. LPL is synthesized predominantly in adipose, heart, and skeletal muscle and is adherent to vascular endothelium of extrahepatic tissues; its activity is regulated and is tissue specific. HL is synthesized only in the liver, is bound to hepatic sinusoidal vascular endothelium, and functions only in the liver. The principal in vivo substrates of LPL and HL are TGs and PL. LPL requires apoC-II as a cofactor; HL has no required cofactors. LPL serves the first phase of lipolysis of VLDL and chylomicrons (Figure 1); it rapidly hydrolyzes core TGs, resulting in the shedding of the redundant surface from these particles as lipid-poor apoA-I and/or apoE PL-UC disks (Figure 1). These coalesce with larger HDL or acquire PL and UC from ABCA1 (see Figure 1). Lypolysis of VLDL- and chylomicron-remnant particles involves LPL,108 but also (increasingly) HL, as their size diminishes. HL hydrolysis of core TGs in HDL2 and HDL3 is most efficient for Lp(A-I, A-II). Lipases influence HDL levels; among the general population, LPL is positively associated with HDL and HDL2 levels109 and is negatively associated with their catabolism,110 whereas HL has an inverse association that is particularly strong for HDL2-C levels111 and for LDL particle size.112,113
Regulation of LPL and HL activity is under investigation. A growing body of evidence points to the modulation by activated LXR and RXR nuclear receptor heterodimers of the expression of certain of the genes regulating lipoprotein metabolism, including LPL114,115 and sterol regulatory element binding protein-1.116–118
Little is known about the roles and regulation of EL,119 which is of interest because of its high degree of phospholipase activity.
SR Class B Type I
SR-BI120, an 82-kDa protein of the CD36 family, mediates selective uptake of HDL-C and CE121 in the liver, steroidogenic tissues, and macrophages.122 It also binds LDL at a separate receptor domain.123 SR-BI–independent mechanisms also appear to mediate selective CE uptake from HDL3.124–126 In the liver, SR-BI, expressed on apical and basolateral plasma membranes, plays a key role in the uptake of HDL CE and its sorting, processing, and excretion in bile.127 In an in vitro system, the rate of CE-selective uptake from donor HDL particles is proportional to the amount of CE initially present on particles, suggesting that the principal contributors to this transport process are the larger HDL2s.128 It is proposed that HDL cholesterol, the principal source of biliary cholesterol, is first taken up as a particle by SR-BI into the hepatocyte endosome system and that by selective endosome sorting, the cholesterol is removed, and the lipid-poor HDL is resecreted (Figure 1) into plasma.127
SR-BI deficiency in mice selectively diminishes biliary cholesterol secretion without diminishing bile acid or PL secretion; SR-BI deficiency does not impair absorption of dietary cholesterol. Overexpression of SR-BI in liver reduces VLDL- and LDL-apoB as well as HDL levels, increases reverse cholesterol transport,129 and decreases susceptibility to atherosclerosis.130 Conversely, genetic downregulation of SR-BI activity in susceptible mice increases atherosclerosis.131 Probucol, a potent antioxidant, markedly increases SR-BI–mediated selective HDL CE uptake in intact mouse liver and in SR-BI–expressing hamster ovary cells in culture. This occurs without increased SR-BI membrane protein, apparently by a size-independent alteration of the probucol-carrying HDL that enhances the HDL–SR-BI interaction.132
Regulation of SR-BI expression is under active investigation. PPAR activators acting through RXR heterodimers have substantially increased the expression of SR-BI in differentiated human macrophages and in apoE-null mouse atherosclerotic plaque.122 PPAR and PPAR
are expressed in such macrophages, as is the human analogue of murine SR-BI. By extrapolation, increased expression of SR-BI with ligands for PPARs and possibly for RXRs should reduce LDL-C and HDL-C, accelerate reverse cholesterol transport, and decrease atherosclerosis. This is consistent with early clinical experience, except that HDL-C is modestly increased,133 suggesting other loci of gene regulation by these ligands in vivo.
Megalin/Cubulin
Among the largest plasma membrane proteins yet described, these 2 are colocalized on the apical brush border of renal tubular cells134 and ileal enterocytes. Megalin (LDLR-related protein [LRP]-2) is an 500-kDa member of the LRP family, which is thought to depend on cooperation with membrane-anchored cell surface receptors to promote LRP-mediated endocytosis of the ligand. Cubulin is a 460-kDa membrane surface receptor that binds the smallest HDL particles that normally appear in the glomerular filtrate, particles <8 nm in diameter,135 which constitute up to 8% of plasma apoA-I.136 These lipid-poor HDLs are shown in Figure 1 as acceptors of UC and PL from ABCA1 and are shown in Figure 2 as HDL3c. Once the megalin-cubulin-HDL3c complex is internalized, the ligand is separated from the receptor, which is recycled to the cell surface while HDL undergoes lysosomal degradation.137 The expression of both receptors in vitro is increased by RA, but not by sterol depletion.137 Increased renal catabolism of HDL3c by upregulation of this receptor complex could deplete this precursor of HDL3 and HDL2 and, thus, may plausibly explain the HDL2-lowering effects of our antioxidant cocktail. However, the rate-limiting factor for this mechanism of HDL catabolism is more likely to be the plasma concentration of HDL3c, the principal determinant of its appearance in the glomerular filtrate.138 Therefore, we doubt that the antioxidant effect in question is mediated by enhanced megalin/cubulin expression.
|
In the End, the Chemistry Just Wasn’t Right |
|---|
|
TopAbstractThe RomanceThe Dream FadesAnd Now, IncompatibilityWith Hindsight, It Was...Who Was to Blame?Our Relationship Was Just...In the End, the...Can We Still be...References |
|---|
We have attempted to explain why adding an antioxidant vitamin cocktail to LDL-lowering and HDL-raising therapy blunts the expected increase in HDL2-C, Lp(A-I), and HDL particle size while appearing to diminish the antiatherogenic and favorable clinical effects of lipid therapy. To do so, we have reviewed current understanding of the actions and regulation of individual components of the reverse cholesterol transport pathways.
From the present review, one would predict that selective downregulation of the expression of apoA-I, ABCA1, LCAT, and SR-BI genes would blunt reverse cholesterol transport and, except for SR-BI, decrease HDL2-C. Thus, diminished apoA-I, ABCA1, and LCAT gene expression appear to be potential candidates to explain the antioxidant effects. However, LCAT activity has not been shown to be altered by vitamin E.
The effects of increasing CETP activity on reverse transport are not so easily predictable. CETP-mediated transfer of CE to apoB-containing particles may prove to be proatherogenic, particularly if the LDLRs are downregulated and the recipient particles contain atherogenic apolipoproteins (eg, apoC-III and apoE4/E4; see Figure 1). Consistent with this, we have the clinical result that a powerful antioxidant, probucol, increases measured CETP activity, strikingly decreases HDL-C and HDL2-C, and, if anything, promotes atherogenesis.30,31 Vitamin E has been shown to have similar effects on CETP.100 Thus, CETP activation appears to be a prime suspect in the antioxidant effects observed in HATS.28
Antioxidant-mediated upregulation of SR-BI expression or enhancement of its HDL interaction132 would reduce HDL2-C levels but should also lower LDL-C and favorably effect atherogenesis. For these reasons, increased SR-BI expression appears to be an unlikely candidate to explain the antioxidant effect in question.
Downregulation of hepatic lipase activity by intensive lipid therapy results in increased HDL2-C and decreased atherosclerosis, apparently via an LDL-size effect.113 A blunting of this response by antioxidants would simulate the findings in HATS; thus, upregulation of HL activity by antioxidants is another candidate mechanism. However, we lack sufficient understanding of HL regulation to make speculations.
Although human LPL activity is correlated with HDL2-C levels and inversely with HDL catabolism and although LPL activity may be modulated by oxysterol-activated LXR nuclear receptors,117,118 the lack of effect of our antioxidants on the TG response to simvastatin-niacin (see Table 2) suggests that the antioxidant effect in question is not mediated by changes in LPL.
By the above reasoning, the possible culprits for the antioxidant effect in question may be boiled down to 3: (1) decreased hepatic or intestinal apoA-I synthesis (or its increased catabolism), (2) decreased macrophage ABCA1 expression, and/or (3) increased CETP activity. The latter has been confirmed for vitamin E.
A common thread among these mechanisms is the role played by oxysterol-activated LXR, the 9-cis-RA–activated RXR, and (to a lesser extent) the RA-activated RAR nuclear receptors in regulating the cell-specific expression of each of these genes. LXR nuclear receptors also regulate the transcription of several other genes responsible for cholesterol metabolism, including LPL,114 ABCG1, ABCG5, ABCG8, apoE, and CYP7A1.49,139,140 One could postulate that fat-soluble antioxidant vitamins, entering cells on endocytosed LDL or HDL, might diminish oxysterol/oxidative stress–related activation of LXR or that RA (from ß-carotene) might competitively interfere with 9-cis-RA activation of RXR, both resulting in the diminished expression of apoA-I and/or ABCA1. Alternatively, by decreasing the intimal concentration of oxidized LDL,28 these vitamins may indirectly downregulate the LXR-responsive ABCA151 gene. Or, simultaneous hepatic upregulation of CETP expression94,95,100 and downregulation of apoA-I synthesis, mediated by a putative antioxidant activation of ARP-1, could cause the HDL2-C effects under consideration.
|
Can We Still be Friends? |
|---|
|
TopAbstractThe RomanceThe Dream FadesAnd Now, IncompatibilityWith Hindsight, It Was...Who Was to Blame?Our Relationship Was Just...In the End, the...Can We Still be...References |
|---|
Should antioxidant vitamins be combined with lipid therapy under any circumstances? The large prospective trials20–24 (see Table 1) do not demonstrate any benefit from individual antioxidant vitamins given without lipid therapy. However, might there be a favorable interaction between these 2 treatments, enhancing the benefits of lipid therapy? Our HATS trial showed no significant benefit from the vitamin cocktail given alone; furthermore, the combined therapies interacted adversely, actually detracting from the benefits of lipid therapy. The recently published Heart Protection Study,141 which compared antioxidant vitamins versus their placebos in a factorial design with simvastatin (40 mg QD) versus its placebo, showed no cardiovascular (or nonvascular) benefit from a combination of vitamins similar to the combinations in HATS. Indeed, there were small but highly significant in-treatment differences between the antioxidant vitamin and antioxidant placebo groups in LDL-C, TG, and HDL-C levels (P<0.0001), predictably favoring placebo, and there was a nonsignificant trend (P=0.3) toward a 5% cardiovascular mortality increase (see Table 1).
Thus, the totality of evidence for currently studied antioxidant vitamins demonstrates that they are of no benefit to the general population at high or at low cardiovascular risk when taken for the prevention of native vascular disease (or cancer); other proposed special indications142–146 require further prospective proof of benefit. Indeed, by creating a diversion from proven therapies, the use of these antioxidants may actually do harm. Furthermore, our HATS trial, if confirmed, raises the important caveat that therapies designed to substantially raise HDL2 should not be combined with antioxidant vitamins.28 It is important to distinguish the current negative results of antioxidant trials from the prevailing view that oxidation of LDL contributes importantly to atherogenesis. Eventually, more powerful, appropriately targeted, or less HDL-2 adverse antioxidants may be proven to be protective.
We conclude that by analogy, the farmer and the cowgirl (antioxidants and lipid drugs) could be friends, but at best, the relationship would be platonic, and it could get nasty.
|
Acknowledgments |
|---|
This study was supported by National Institutes of Health (NIH) grant R01 HL-49546, with drug supplies from Upsher-Smith Laboratories and Merck & Co, in part by the Clinical Nutrition Research Unit (NIH DK-35816), and in part by the Diabetes Endocrinology Research Center (NIH DK-17047). A portion of this study was performed in the Clinical Research Center (NIH MO1-00037) at the University of Washington. We are grateful for the insightful comments of John Brunzell, MD, and the superb graphical contributions of Heather Bruggman in her preparation of the manuscript.
Received July 15, 2002; accepted July 29, 2002.
|
References |
|---|
|
TopAbstractThe RomanceThe Dream FadesAnd Now, IncompatibilityWith Hindsight, It Was...Who Was to Blame?Our Relationship Was Just...In the End, the...Can We Still be...References |
|---|
1. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med. 1993; 328: 1444–1449.
2. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med. 1993; 328: 1450–1456.
3. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991; 88: 1785–1792.[Medline] [Order article via Infotrieve]
4. Esterbauer H, Gebicki J, Puhl H, Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med. 1992; 13: 341–390.[CrossRef][Medline] [Order article via Infotrieve]
5. Parthasarathy S, Young SG, Witztum JL, Pittman RC, Steinberg D. Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest. 1986; 77: 641–644.[Medline] [Order article via Infotrieve]
6. Sparrow CP, Doebber TW, Olszewski J, Wu MS, Ventre J, Stevens KA, Chao YS. Low density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholesterol-fed rabbits by the antioxidant N,N'-diphenyl-phenylenediamine. J Clin Invest. 1992; 89: 1885–1891.[Medline] [Order article via Infotrieve]
7. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci U S A. 1987; 84: 7725–7729.
8. Sasahara M, Raines EW, Chait A, Carew TE, Steinberg D, Wahl PW, Ross R. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol, I: is the extent of atherosclerosis related to resistance of LDL to oxidation? J Clin Invest. 1994; 94: 155–164.[Medline] [Order article via Infotrieve]
9. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J. 1993; 69: 377–381.
10. Henney AM, Wakeley PR, Davies MJ, Foster K, Hembry R, Murphy G, Humphries S. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci U S A. 1991; 88: 8154–8158.
11. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995; 91: 2844–2850.
12. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 1993; 87: 1781–1791.
13. Brown BG, Gallery CA, Badger RS, Kennedy JW, Mathey D, Bolson EL, Dodge HT. Incomplete lysis of thrombus in the moderate underlying atherosclerotic lesion during intracoronary infusion of streptokinase for acute myocardial infarction: quantitative angiographic observations. Circulation. 1986; 73: 653–661.
14. Guyton JR, Klemp KF. Development of the atherosclerotic core region: chemical and ultrastructural analysis of microdissected atherosclerotic lesions from human aorta. Arterioscler Thromb. 1994; 14: 1305–1314.
15. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989; 320: 915–924.[Medline] [Order article via Infotrieve]
16. Brown B, Zhao X-Q. Lipid-lowering therapy. In: Hennekens C, ed. Clinical Trials in Cardiovascular Disease. Philadelphia, Pa: WB Saunders; 1999: 199–216.
17. The Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease. N Engl J Med. 1998; 339: 1349–1359.
18. Steinberg D. Antioxidant vitamins and coronary heart disease. N Engl J Med. 1993; 328: 1487–1489.
19. Witztum JL. Basic requirements for investigational new drug and new drug application approval for an antioxidant compound in cardiovascular disease. Am J Cardiol. 1998; 81: 50F–51F.[CrossRef][Medline] [Order article via Infotrieve]
20. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000; 342: 154–160.
21. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 1999; 354: 447–455.[CrossRef][Medline] [Order article via Infotrieve]
22. Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 1994; 330: 1029–1035.
23. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996; 347: 781–786.[CrossRef][Medline] [Order article via Infotrieve]
24. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, Belanger C, LaMotte F, Gaziano JM, Ridker PM, Willett W, Peto R. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 1996; 334: 1145–1149.
25. Heinecke JW. Is the emperor wearing clothes?: clinical trials of vitamin E and the LDL oxidation hypothesis. Arterioscler Thromb Vasc Biol. 2001; 21: 1261–1264.
26. Brown BG, Zhao XQ, Chait A, Frohlich J, Cheung M, Heise N, Dowdy A, DeAngelis D, Fisher LD, Albers J. Lipid altering or antioxidant vitamins for patients with coronary disease and very low HDL cholesterol?: the HDL-Atherosclerosis Treatment Study Design. Can J Cardiol. 1998; 14 (suppl A): 6A–13A.[Medline] [Order article via Infotrieve]
27. Cheung MC, Zhao XQ, Chait A, Albers JJ, Brown BG. Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arterioscler Thromb Vasc Biol. 2001; 21: 1320–1326.
28. Brown BG, Zhao X-Q, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, ALaupovic P, Frohlich J, Albers JJ. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001; 345: 1583–1592.
29. Zhao XQ, Yuan C, Hatsukami TS, Frechette EH, Kang XJ, Maravilla KR, Brown BG. Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case-control study. Arterioscler Thromb Vasc Biol. 2001; 21: 1623–1629.
30. Walldius G, Erikson U, Olsson AG, Bergstrand L, Hadell K, Johansson J, Kaijser L, Lassvik C, Molgaard J, Nilsson S. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol. 1994; 74: 875–883.[CrossRef][Medline] [Order article via Infotrieve]
31. Johansson J, Olsson AG, Bergstrand L, Elinder LS, Nilsson S, Erikson U, Molgaard J, Holme I, Walldius G. Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia: a Probucol Quantitative Regression Swedish Trial (PQRST) Report. Arterioscler Thromb Vasc Biol. 1995; 15: 1049–1056.
32. O’Leary TJ, Simo IE, Kanigsberg N, Walker J, Goodall JC, Ooi TC. Changes in serum lipoproteins and high-density lipoprotein composition during isotretinoin therapy. Clin Invest Med. 1987; 10: 355–360.[Medline] [Order article via Infotrieve]
33. Aviram M, Rosenblat M, Bisgaier CL, Newton RS. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis. 1998; 138: 271–280.[CrossRef][Medline] [Order article via Infotrieve]
34. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998; 81: 582–587.[CrossRef][Medline] [Order article via Infotrieve]
35. Lee AC, Morse J, Cheung MC, Zhao X-Q, Chait A, Albers JJ, Brown BG. Effect of individual antioxidant vitamins in suppressing the HDL2-C response to lipid therapy. In: Abstracts from the ATVB Scientific Sessions; April 6–8, 2001; Salt Lake City, Utah.
36. Tall AR, Wang N, Mucksavage P. Is it time to modify the reverse cholesterol transport model? J Clin Invest. 2001; 108: 1273–1275.[CrossRef][Medline] [Order article via Infotrieve]
37. Chisholm JW, Burleson ER, Shelness GS, Parks JS. ApoA-I secretion from HepG2 cells: evidence for the secretion of both lipid-poor apoA-I and intracellularly assembled nascent HDL. J Lipid Res. 2002; 43: 36–44.
38. Traber MG, Kayden HJ, Rindler MJ. Polarized secretion of newly synthesized lipoproteins by the Caco-2 human intestinal cell line. J Lipid Res. 1987; 28: 1350–1363.[Abstract]
39. Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, Deleuze JF, Brewer HB, Duverger N, Denefle P, Assmann G. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet. 1999; 22: 352–355.[CrossRef][Medline] [Order article via Infotrieve]
40. Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, Yu L, Brewer C, Collins JA, Molhuizen HO, Loubser O, Ouelette BF, Fichter K, Ashbourne-Excoffon KJ, Sensen CW, Scherer S, Mott S, Denis M, Martindale D, Frohlich J, Morgan K, Koop B, Pimstone S, Kastelein JJ, Hayden MR. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet. 1999; 22: 336–345.[CrossRef][Medline] [Order article via Infotrieve]
41. Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W, Drobnik W, Barlage S, Buchler C, Porsch-Ozcurumez M, Kaminski WE, Hahmann HW, Oette K, Rothe G, Aslanidis C, Lackner KJ, Schmitz G. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet. 1999; 22: 347–351.[CrossRef][Medline] [Order article via Infotrieve]
42. Lawn RM, Wade DP, Garvin MR, Wang X, Schwartz K, Porter JG, Seilhamer JJ, Vaughan AM, Oram JF. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest. 1999; 104: R25–R31.[Medline] [Order article via Infotrieve]
43. Oram JF, Vaughan AM, Stocker R. ATP-binding cassette transporter A1 mediates cellular secretion of alpha-tocopherol. J Biol Chem. 2001; 276: 39898–39902.
44. Wang N, Silver DL, Thiele C, Tall AR. ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein. J Biol Chem. 2001; 276: 23742–23747.
45. Schmitz G, Langmann T, Structure, function and regulation of the ABC1 gene product. Curr Opin Lipidol. 2001; 12: 129–140.[CrossRef][Medline] [Order article via Infotrieve]
46. Vaisman BL, Lambert G, Amar M, Joyce C, Ito T, Shamburek RD, Cain WJ, Fruchart-Najib J, Neufeld ED, Remaley AT, Brewer HB Jr, Santamarina-Fojo S. ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. J Clin Invest. 2001; 108: 303–309.[CrossRef][Medline] [Order article via Infotrieve]
47. Costet P, Luo Y, Wang N, Tall AR. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem. 2000; 275: 28240–28245.
48. Repa JJ, Turley SD, Lobaccaro JA, Medina J, Li L, Lustig K, Shan B, Heyman RA, Dietschy JM, Mangelsdorf DJ. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science. 2000; 289: 1524–1529.
49. Fu X, Menke JG, Chen Y, Zhou G, MacNaul KL, Wright SD, Sparrow CP, Lund EG. 27-Hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J Biol Chem. 2001; 276: 38378–38387.
50. Venkateswaran A, Laffitte BA, Joseph SB, Mak PA, Wilpitz DC, Edwards PA, Tontonoz P. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc Natl Acad Sci U S A. 2000; 97: 12097–12102.
51. Laffitte BA, Joseph SB, Walczak R, Pei L, Wilpitz DC, Collins JL, Tontonoz P. Autoregulation of the human liver X receptor alpha promoter. Mol Cell Biol. 2001; 21: 7558–7568.
52. Porsch-Ozcurumez M, Langmann T, Heimerl S, Borsukova H, Kaminski WE, Drobnik W, Honer C, Schumacher C, Schmitz G. The zinc finger protein 202 (ZNF202) is a transcriptional repressor of ATP binding cassette transporter A1 (ABCA1) and ABCG1 gene expression and a modulator of cellular lipid efflux. J Biol Chem. 2001; 276: 12427–12433.
53. Wagner S, Hess MA, Ormonde-Hanson P, Malandro J, Hu H, Chen M, Kehrer R, Frodsham M, Schumacher C, Beluch M, Honer C, Skolnick M, Ballinger D, Bowen BR. A broad role for the zinc finger protein ZNF202 in human lipid metabolism. J Biol Chem. 2000; 275: 15685–15690.
54. Betteridge DJ, Illingworth DR, Shepherd J. Lipoproteins in Health and Disease. London: Arnold; 1999.
55. Cheung MC, Lum KD, Brouillette CG, Bisgaier CL. Characterization of apoA-I-containing lipoprotein subpopulations secreted by HepG2 cells. J Lipid Res. 1989; 30: 1429–1436.[Abstract]
56. Segrest JP, Jones MK, Klon AE, Sheldahl CJ, Hellinger M, De Loof H, Harvey SC. A detailed molecular belt model for apolipoprotein A-I in discoidal high density lipoprotein. J Biol Chem. 1999; 274: 31755–31758.
57. Barbaras R, Puchois P, Fruchart JC, Ailhaud G. Cholesterol efflux from cultured adipose cells is mediated by LpAI particles but not by LpAI: AII particles. Biochem Biophys Res Commun. 1987; 142: 63–69.[CrossRef][Medline] [Order article via Infotrieve]
58. Srivastava RA, Srivastava N. High density lipoprotein, apolipoprotein A-I, and coronary artery disease. Mol Cell Biochem. 2000; 209: 131–144.[CrossRef][Medline] [Order article via Infotrieve]
59. Benoit P, Emmanuel F, Caillaud JM, Bassinet L, Castro G, Gallix P, Fruchart JC, Branellec D, Denefle P, Duverger N. Somatic gene transfer of human apoA-I inhibits atherosclerosis progression in mouse models. Circulation. 1999; 99: 105–110.
60. Tangirala RK, Tsukamoto K, Chun SH, Usher D, Pure E, Rader DJ. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation. 1999; 100: 1816–1822.
61. Holvoet P, Peeters K, Lund-Katz S, Mertens A, Verhamme P, Quarck R, Stengel D, Lox M, Deridder E, Bernar H, Nickel M, Theilmeier G, Ninio E, Phillips MC. Arg123-Tyr166 domain of human apoA-I is critical for HDL-mediated inhibition of macrophage homing and early atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2001; 21: 1977–1983.
62. Norum RA, Lakier JB, Goldstein S, Angel A, Goldberg RB, Block WD, Noffze DK, Dolphin PJ, Edelglass J, Bogorad DD, Alaupovic P. Familial deficiency of apolipoproteins A-I and C-III and precocious coronary-artery disease. N Engl J Med. 1982; 306: 1513–1519.[Abstract]
63. Forte TM, Nichols AV, Krauss RM, Norum RA. Familial apolipoprotein AI and apolipoprotein CIII deficiency: subclass distribution, composition, and morphology of lipoproteins in a disorder associated with premature atherosclerosis. J Clin Invest. 1984; 74: 1601–1613.[Medline] [Order article via Infotrieve]
64. Rader DJ, Ikewaki K, Duverger N, Feuerstein I, Zech L, Connor W, Brewer HB Jr. Very low high-density lipoproteins without coronary atherosclerosis. Lancet. 1993; 342: 1455–1458.[CrossRef][Medline] [Order article via Infotrieve]
65. Asami T, Ciomartan T, Uchiyama M. Changes in serum apolipoprotein concentrations after L-thyroxine therapy in infants with congenital hypothyroidism. Metabolism. 1999; 48: 1343–1345.[CrossRef][Medline] [Order article via Infotrieve]
66. Cheung MC, Walden CE, Knopp RH. Comparison of the effects of triphasic oral contraceptives with desogestrel or levonorgestrel on apolipoprotein A-I-containing high- density lipoprotein particles. Metabolism. 1999; 48: 658–664.[CrossRef][Medline] [Order article via Infotrieve]
67. Colvin PL Jr, Auerbach BJ, Case LD, Hazzard WR, Applebaum-Bowden D. A dose-response relationship between sex hormone-induced change in hepatic triglyceride lipase and high-density lipoprotein cholesterol in postmenopausal women. Metabolism. 1991; 40: 1052–1056.[CrossRef][Medline] [Order article via Infotrieve]
68. Brinton EA. Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein A-I and lowers hepatic lipase activity without lowering the fractional catabolic rate. Arterioscler Thromb Vasc Biol. 1996; 16: 431–440.
69. Sakai T, Kamanna VS, Kashyap ML. Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler Thromb Vasc Biol. 2001; 21: 1783–1789.
70. Papazafiri P, Ogami K, Ramji DP, Nicosia A, Monaci P, Cladaras C, Zannis VI. Promoter elements and factors involved in hepatic transcription of the human apoA-I gene positive and negative regulators bind to overlapping sites. J Biol Chem. 1991; 266: 5790–5797.
71. Nakamura T, Fox-Robichaud A, Kikkawa R, Kashiwagi A, Kojima H, Fujimiya M, Wong NC. Transcription factors and age-related decline in apolipoprotein A-I expression. J Lipid Res. 1999; 40: 1709–1718.
72. Cuthbert C, Wang Z, Zhang X, Tam SP. Regulation of human apolipoprotein A-I gene expression by gramoxone. J Biol Chem. 1997; 272: 14954–14960.
73. Staels B, Auwerx J. Regulation of apo A-I gene expression by fibrates. Atherosclerosis. 1998; 137 (suppl): S19–S23.[CrossRef][Medline] [Order article via Infotrieve]
74. Gaudet F, Ginsburg GS. Transcriptional regulation of the cholesteryl ester transfer protein gene by the orphan nuclear hormone receptor apolipoprotein AI regulatory protein-1. J Biol Chem. 1995; 270: 29916–29922.
75. Srivastava RA, Srivastava N, Averna M. Dietary cholic acid lowers plasma levels of mouse and human apolipoprotein A-I primarily via a transcriptional mechanism. Eur J Biochem. 2000; 267: 4272–4280.[Medline] [Order article via Infotrieve]
76. Giller T, Hennes U, Kempen HJ. Regulation of human apolipoprotein A-I expression in Caco-2 and HepG2 cells by all-trans and 9-cis retinoic acids. J Lipid Res. 1995; 36: 1021–1028.[Abstract]
77. Grundy SM, Vega GL. Fibric acids: effects on lipids and lipoprotein metabolism. Am J Med. 1987; 83: 9–20.
78. Fruchart JC, Staels B, Duriez P. PPARS, metabolic disease and atherosclerosis. Pharmacol Res. 2001; 44: 345–352.[CrossRef][Medline] [Order article via Infotrieve]
79. van ‘t Hooft FM, Ruotolo G, Boquist S, de Faire U, Eggertsen G, Hamsten A. Human evidence that the apolipoprotein a-II gene is implicated in visceral fat accumulation and metabolism of triglyceride-rich lipoproteins. Circulation. 2001; 104: 1223–1228.
80. Schultz JR, Verstuyft JG, Gong EL, Nichols AV, Rubin EM. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature. 1993; 365: 762–764.[CrossRef][Medline] [Order article via Infotrieve]
81. Tailleux A, Bouly M, Luc G, Castro G, Caillaud JM, Hennuyer N, Poulain P, Fruchart JC, Duverger N, Fievet C. Decreased susceptibility to diet-induced atherosclerosis in human apolipoprotein A-II transgenic mice. Arterioscler Thromb Vasc Biol. 2000; 20: 2453–2458.
82. Castellani LW, Lusis AJ. ApoA-II versus ApoA-I: two for one is not always a good deal. Arterioscler Thromb Vasc Biol. 2001; 21: 1870–1872.
83. Cheung MC, Wolf AC, Lum KD, Tollefson JH, Albers JJ. Distribution and localization of lecithin: cholesterol acyltransferase and cholesteryl ester transfer activity in A-I-containing lipoproteins. J Lipid Res. 1986; 27: 1135–1144.[Abstract]
84. Glomset JA. The plasma lecithins: cholesterol acyltransferase reaction. J Lipid Res. 1968; 9: 155–167.[Abstract]
85. Hoeg JM, Santamarina-Fojo S, Berard AM, Cornhill JF, Herderick EE, Feldman SH, Haudenschild CC, Vaisman BL, Hoyt RF Jr, Demosky SJ, Jr, Kauffman RD, Hazel CM, Marcovina SM, Brewer HB Jr. Overexpression of lecithin: cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc Natl Acad Sci U S A. 1996; 93: 11448–11453.
86. Berard AM, Foger B, Remaley A, Shamburek R, Vaisman BL, Talley G, Paigen B, Hoyt RF Jr, Marcovina S, Brewer HB Jr, Santamarina-Fojo S. High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase. Nat Med. 1997; 3: 744–749.[CrossRef][Medline] [Order article via Infotrieve]
87. Mehrabian M, Castellani LW, Wen PZ, Wong J, Rithaporn T, Hama SY, Hough GP, Johnson D, Albers JJ, Mottino GA, Frank JS, Navab M, Fogelman AM, Lusis AJ. Genetic control of HDL levels and composition in an interspecific mouse cross (CAST/Ei x C57BL/6J). J Lipid Res. 2000; 41: 1936–1946.
88. Napoli C, Leccese M, Palumbo G, de Nigris F, Chiariello P, Zuliani P, Somma P, Di Loreto M, De Matteis C, Cacciatore F, Abete P, Liguori A, Chiariello M, D’Armiento FP. Effects of vitamin E and HMG-CoA reductase inhibition on cholesteryl ester transfer protein and lecithin-cholesterol acyltransferase in hypercholesterolemia. Coron Artery Dis. 1998; 9: 257–264.[Medline] [Order article via Infotrieve]
89. Duverger N, Rader D, Brewer HB Jr. Distribution of subclasses of HDL containing apoA-I without apoA-II (LpA-I) in normolipidemic men and women. Arterioscler Thromb. 1994; 14: 1594–1599.
90. Barter PJ, Rye KA. Cholesteryl ester transfer protein, high density lipoprotein and arterial disease. Curr Opin Lipidol. 2001; 12: 377–382.[CrossRef][Medline] [Order article via Infotrieve]
91. Plump AS, Masucci-Magoulas L, Bruce C, Bisgaier CL, Breslow JL, Tall AR. Increased atherosclerosis in apoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler Thromb Vasc Biol. 1999; 19: 1105–1110.
92. Yamashita S, Hirano K, Sakai N, Matsuzawa Y. Molecular biology and pathophysiological aspects of plasma cholesteryl ester transfer protein. Biochim Biophys Acta. 2000; 1529: 257–275.[Medline] [Order article via Infotrieve]
93. Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Bruschke AV, Lie KI, Kastelein JJ. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis: the Regression Growth Evaluation Statin Study Group. N Engl J Med. 1998; 338: 86–93.
94. Franceschini G, Chiesa G, Sirtori CR. Probucol increases cholesteryl ester transfer protein activity in hypercholesterolaemic patients. Eur J Clin Invest. 1991; 21: 384–388.[Medline] [Order article via Infotrieve]
95. Bagdade JD, Kaufman D, Ritter MC, Subbaiah PV. Probucol treatment in hypercholesterolemic patients: effects on lipoprotein composition, HDL particle size, and cholesteryl ester transfer. Atherosclerosis. 1990; 84: 145–154.[CrossRef][Medline] [Order article via Infotrieve]
96. Agerholm-Larsen B, Tybjaerg-Hansen A, Schnohr P, Steffensen R, Nordestgaard BG. Common cholesteryl ester transfer protein mutations, decreased HDL cholesterol, and possible decreased risk of ischemic heart disease: the Copenhagen City Heart Study. Circulation. 2000; 102: 2197–2203.
97. Zhong S, Sharp DS, Grove JS, Bruce C, Yano K, Curb JD, Tall AR. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest. 1996; 97: 2917–2923.[Medline] [Order article via Infotrieve]
98. Marzetta CA, Meyers TJ, Albers JJ. Lipid transfer protein-mediated distribution of HDL-derived cholesteryl esters among plasma apoB-containing lipoprotein subpopulations. Arterioscler Thromb. 1993; 13: 834–841.
99. Luo Y, Liang CP, Tall AR. The orphan nuclear receptor LRH-1 potentiates the sterol-mediated induction of the human CETP gene by liver X receptor. J Biol Chem. 2001; 276: 24767–24773.
100. Arrol S, Mackness MI, Durrington PN. Vitamin E supplementation increases the resistance of both LDL and HDL to oxidation and increases cholesteryl ester transfer activity. Atherosclerosis. 2000; 150: 129–134.[CrossRef][Medline] [Order article via Infotrieve]
101. Tall AR, Krumholz S, Olivecrona T, Deckelbaum RJ. Plasma phospholipid transfer protein enhances transfer and exchange of phospholipids between very low density lipoproteins and high density lipoproteins during lipolysis. J Lipid Res. 1985; 26: 842–851.[Abstract]
102. Cheung MC, Wolfbauer G, Albers JJ. Plasma phospholipid mass transfer rate: relationship to plasma phospholipid and cholesteryl ester transfer activities and lipid parameters. Biochim Biophys Acta. 1996; 1303: 103–110.[Medline] [Order article via Infotrieve]
103. Jauhiainen M, Metso J, Pahlman R, Blomqvist S, van Tol A, Ehnholm C. Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J Biol Chem. 1993; 268: 4032–4036.
104. Lusa S, Jauhiainen M, Metso J, Somerharju P, Ehnholm C. The mechanism of human plasma phospholipid transfer protein-induced enlargement of high-density lipoprotein particles: evidence for particle fusion. Biochem J. 1996; 313: 275–282.[Medline] [Order article via Infotrieve]
105. Albers JJ, Wolfbauer G, Cheung MC, Day JR, Ching AF, Lok S, Tu AY. Functional expression of human and mouse plasma phospholipid transfer protein: effect of recombinant and plasma PLTP on HDL subspecies. Biochim Biophys Acta. 1995; 1258: 27–34.[Medline] [Order article via Infotrieve]
106. Cheung MC, Wolfbauer G, Brown BG, Albers JJ. Relationship between plasma phospholipid transfer protein activity and HDL subclasses among patients with low HDL and cardiovascular disease. Atherosclerosis. 1999; 142: 201–205.[CrossRef][Medline] [Order article via Infotrieve]
107. Cheung MC, Wolfbauer G, Kennedy H, Brown BG, Albers JJ. Plasma phospholipid transfer protein activity in patients with low HDL and cardiovascular disease treated with simvastatin and niacin. Biochim Biophys Acta. 2001; 1537: 117–124.[Medline] [Order article via Infotrieve]
108. Barbagallo CM, Fan J, Blanche PJ, Rizzo M, Taylor JM, Krauss RM. Overexpression of human hepatic lipase and ApoE in transgenic rabbits attenuates response to dietary cholesterol and alters lipoprotein subclass distributions. Arterioscler Thromb Vasc Biol. 1999; 19: 625–632.
109. Barter PJ. Enzymes involved in lipid and lipoprotein metabolism. Curr Opin Lipidol. 1990; 1: 518–523.[CrossRef]
110. Frenais R, Nazih H, Ouguerram K, Maugeais C, Zair Y, Bard JM, Charbonnel B, Magot T, Krempf M. In vivo evidence for the role of lipoprotein lipase activity in the regulation of apolipoprotein AI metabolism: a kinetic study in control subjects and patients with type II diabetes mellitus. J Clin Endocrinol Metab. 2001; 86: 1962–1967.
111. Zambon A, Deeb SS, Brown BG, Hokanson JE, Brunzell JD. Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. Circulation. 2001; 103: 792–798.
112. Zambon A, Austin MA, Brown BG, Hokanson JE, Brunzell JD. Effect of hepatic lipase on LDL in normal men and those with coronary artery disease. Arterioscler Thromb. 1993; 13: 147–153.
113. Zambon A, Hokanson JE, Brown BG, Brunzell JD. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation. 1999; 99: 1959–1964.
114. Zhang Y, Repa JJ, Gauthier K, Mangelsdorf DJ. Regulation of lipoprotein lipase by the oxysterol receptors, LXRalpha and LXRbeta. J Biol Chem. 2001; 276: 43018–43024.
115. Davies PJ, Berry SA, Shipley GL, Eckel RH, Hennuyer N, Crombie DL, Ogilvie KM, Peinado-Onsurbe J, Fievet C, Leibowitz MD, Heyman RA, Auwerx J. Metabolic effects of rexinoids: tissue-specific regulation of lipoprotein lipase activity. Mol Pharmacol. 2001; 59: 170–176.
116. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 1997; 89: 331–340.[CrossRef][Medline] [Order article via Infotrieve]
117. Yoshikawa T, Shimano H, Amemiya-Kudo M, Yahagi N, Hasty AH, Matsuzaka T, Okazaki H, Tamura Y, Iizuka Y, Ohashi K, Osuga J, Harada K, Gotoda T, Kimura S, Ishibashi S, Yamada N. Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter. Mol Cell Biol. 2001; 21: 2991–3000.
118. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, Schwendner S, Wang S, Thoolen M, Mangelsdorf DJ, Lustig KD, Shan B. Role of LXRs in control of lipogenesis. Genes Dev. 2000; 14: 2831–2838.
119. Rader DJ, Dugi KA. The endothelium and lipoproteins: insights from recent cell biology and animal studies. Semin Thromb Hemost. 2000; 26: 521–528.[CrossRef][Medline] [Order article via Infotrieve]
120. Trigatti B, Rigotti A, Krieger M. The role of the high-density lipoprotein receptor SR-BI in cholesterol metabolism. Curr Opin Lipidol. 2000; 11: 123–131.[CrossRef][Medline] [Order article via Infotrieve]
121. Glass C, Pittman RC, Weinstein DB, Steinberg D. Dissociation of tissue uptake of cholesterol ester from that of apoprotein A-I of rat plasma high density lipoprotein: selective delivery of cholesterol ester to liver, adrenal, and gonad. Proc Natl Acad Sci U S A. 1983; 80: 5435–5439.
122. Chinetti G, Gbaguidi FG, Griglio S, Mallat Z, Antonucci M, Poulain P, Chapman J, Fruchart JC, Tedgui A, Najib-Fruchart J, Staels B. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation. 2000; 101: 2411–2417.
123. Gu X, Lawrence R, Krieger M. Dissociation of the high density lipoprotein and low density lipoprotein binding activities of murine scavenger receptor class B type I (mSR-BI) using retrovirus library-based activity dissection. J Biol Chem. 2000; 275: 9120–9130.
124. Thuren T. Hepatic lipase and HDL metabolism. Curr Opin Lipidol. 2000; 11: 277–283.[CrossRef][Medline] [Order article via Infotrieve]
125. Rinninger F, Kaiser T, Mann WA, Meyer N, Greten H, Beisiegel U. Lipoprotein lipase mediates an increase in the selective uptake of high density lipoprotein-associated cholesteryl esters by hepatic cells in culture. J Lipid Res. 1998; 39: 1335–1348.
126. Rinninger F, Brundert M, Brosch I, Donarski N, Budzinski RM, Greten H. Lipoprotein lipase mediates an increase in selective uptake of HDL-associated cholesteryl esters by cells in culture independent of scavenger receptor BI. J Lipid Res. 2001; 42: 1740–1751.
127. Silver DL, Tall AR. The cellular biology of scavenger receptor class B type I. Curr Opin Lipidol. 2001; 12: 497–504.[CrossRef][Medline] [Order article via Infotrieve]
128. Rodrigueza WV, Thuahnai ST, Temel RE, Lund-Katz S, Phillips MC, Williams DL. Mechanism of scavenger receptor class B type I-mediated selective uptake of cholesteryl esters from high density lipoprotein to adrenal cells. J Biol Chem. 1999; 274: 20344–20350.
129. Kozarsky KF, Donahee MH, Rigotti A, Iqbal SN, Edelman ER, Krieger M. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature. 1997; 387: 414–417.[CrossRef][Medline] [Order article via Infotrieve]
130. Arai T, Wang N, Bezouevski M, Welch C, Tall AR. Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene. J Biol Chem. 1999; 274: 2366–2371.
131. Trigatti B, Rayburn H, Vinals M, Braun A, Miettinen H, Penman M, Hertz M, Schrenzel M, Amigo L, Rigotti A, Krieger M. Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology. Proc Natl Acad Sci U S A. 1999; 96: 9322–9327.
132. Rinninger F, Wang N, Ramakrishnan R, Jiang XC, Tall AR. Probucol enhances selective uptake of HDL-associated cholesteryl esters in vitro by a scavenger receptor B-I-dependent mechanism. Arterioscler Thromb Vasc Biol. 1999; 19: 1325–1332.
133. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987; 317: 1237–1245.[Abstract]
134. Moestrup SK, Kozyraki R, Kristiansen M, Kaysen JH, Rasmussen HH, Brault D, Pontillon F, Goda FO, Christensen EI, Hammond TG, Verroust PJ. The intrinsic factor-vitamin B12 receptor and target of teratogenic antibodies is a megalin-binding peripheral membrane protein with homology to developmental proteins. J Biol Chem. 1998; 273: 5235–5242.
135. Hammad SM, Stefansson S, Twal WO, Drake CJ, Fleming P, Remaley A, Brewer HB Jr, Argraves WS. Cubilin, the endocytic receptor for intrinsic factor-vitamin B(12) complex, mediates high-density lipoprotein holoparticle endocytosis. Proc Natl Acad Sci U S A. 1999; 96: 10158–10163.
136. Neary RH, Gowland E. Stability of free apolipoprotein A-1 concentration in serum, and its measurement in normal and hyperlipidemic subjects. Clin Chem. 1987; 33: 1163–1169.
137. Hammad SM, Barth JL, Knaak C, Argraves WS. Megalin acts in concert with cubilin to mediate endocytosis of high density lipoproteins. J Biol Chem. 2000; 275: 12003–12008.
138. Horowitz BS, Goldberg IJ, Merab J, Vanni TM, Ramakrishnan R, Ginsberg HN. Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. J Clin Invest. 1993; 91: 1743–1752.[Medline] [Order article via Infotrieve]
139. Lehmann JM, Kliewer SA, Moore LB, Smith-Oliver TA, Oliver BB, Su JL, Sundseth SS, Winegar DA, Blanchard DE, Spencer TA, Willson TM. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem. 1997; 272: 3137–3140.
140. Fitzgerald ML, Moore KJ, Freeman MW. Nuclear hormone receptors and cholesterol trafficking: the orphans find a new home. J Mol Med. 2002; 80: 271–281.[CrossRef][Medline] [Order article via Infotrieve]
141. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 "high-risk" individuals: a randomized placebo-controlled trial. Lancet. 2002; 360: 23–33.[CrossRef][Medline] [Order article via Infotrieve]
142. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, Green MS. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet. 2000; 356: 1213–1218.[CrossRef][Medline] [Order article via Infotrieve]
143. Schneider JE, Berk BC, Gravanis MB, Santoian EC, Cipolla GD, Tarazona N, Lassegue B, King SB III. Probucol decreases neointimal formation in a swine model of coronary artery balloon injury: a possible role for antioxidants in restenosis. Circulation. 1993; 88: 628–637.
144. Yokoi H, Daida H, Kuwabara Y, Nishikawa H, Takatsu F, Tomihara H, Nakata Y, Kutsumi Y, Ohshima S, Nishiyama S, Seki A, Kato K, Nishimura S, Kanoh T, Yamaguchi H. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial. J Am Coll Cardiol. 1997; 30: 855–862.[Abstract]
145. O’Keefe JH Jr, Stone GW, McCallister BD Jr, Maddex C, Ligon R, Kacich RL, Kahn J, Cavero PG, Hartzler GO, McCallister BD. Lovastatin plus probucol for prevention of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1996; 77: 649–652.[CrossRef][Medline] [Order article via Infotrieve]
146. Cote G, Tardif JC, Lesperance J, Lambert J, Bourassa M, Bonan R, Gosselin G, Joyal M, Tanguay JF, Nattel S, Gallo R, Crepeau J. Effects of probucol on vascular remodeling after coronary angioplasty: Multivitamins and Protocol Study Group. Circulation. 1999; 99: 30–35.
147. Cheung MC, Nichols AV, Blanche PJ, Gong EL, Franceschini G, Sirtori CR. Characterization of A-I-containing lipoproteins in subjects with A-I Milano variant. Biochim Biophys Acta. 1988; 960: 73–82.[Medline] [Order article via Infotrieve]
148. Blanche PJ, Gong EL, Forte TM, Nichols AV. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta. 1981; 665: 408–419.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  S. Blum, U. Milman, C. Shapira, R. Miller-Lotan, L. Bennett, M. Kostenko, M. Landau, S. Keidar, Y. Levy, A. Khemlin, et al. Dual Therapy With Statins and Antioxidants Is Superior to Statins Alone in Decreasing the Risk of Cardiovascular Disease in a Subgroup of Middle-Aged Individuals With Both Diabetes Mellitus and the Haptoglobin 2-2 Genotype Arterioscler. Thromb. Vasc. Biol., March 1, 2008; 28(3): e18 - e20. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Pirillo, P. Uboldi, G. Pappalardo, H. Kuhn, and A. L. Catapano Modification of HDL3 by mild oxidative stress increases ATP-binding cassette transporter 1-mediated cholesterol efflux Cardiovasc Res, August 1, 2007; 75(3): 566 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Torzewski, V. Ochsenhirt, A. L. Kleschyov, M. Oelze, A. Daiber, H. Li, H. Rossmann, S. Tsimikas, K. Reifenberg, F. Cheng, et al. Deficiency of Glutathione Peroxidase-1 Accelerates the Progression of Atherosclerosis in Apolipoprotein E-Deficient Mice Arterioscler. Thromb. Vasc. Biol., April 1, 2007; 27(4): 850 - 857. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Singh, J. Otvos, A. Dasgupta, J. A. de Lemos, S. Devaraj, and I. Jialal High-Dose {alpha}-Tocopherol Therapy Does Not Affect HDL Subfractions in Patients with Coronary Artery Disease on Statin Therapy Clin. Chem., March 1, 2007; 53(3): 525 - 528. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Gillies and E. S. Krul Using Genetic Variation to Optimize Nutritional Preemption J. Nutr., January 1, 2007; 137(1): 270S - 274S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Fletcher, K. Berra, P. Ades, L. T. Braun, L. E. Burke, J. L. Durstine, J. M. Fair, G. F. Fletcher, D. Goff, L. L. Hayman, et al. Managing Abnormal Blood Lipids: A Collaborative Approach Circulation, November 15, 2005; 112(20): 3184 - 3209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Lichtenstein and R. M. Russell Essential Nutrients: Food or Supplements?: Where Should the Emphasis Be? JAMA, July 20, 2005; 294(3): 351 - 358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. G. Brown and J. Crowley Is There Any Hope for Vitamin E? JAMA, March 16, 2005; 293(11): 1387 - 1390. [Full Text] [PDF]
|
|
|
|
 |
|
 T. S. E. Albert, P. N. Duchateau, S. S. Deeb, C. R. Pullinger, M. H. Cho, D. C. Heilbron, M. J. Malloy, J. P. Kane, and B. G. Brown Apolipoprotein L-I is positively associated with hyperglycemia and plasma triglycerides in CAD patients with low HDL J. Lipid Res., March 1, 2005; 46(3): 469 - 474. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W Anderson Whole grains and coronary heart disease: the whole kernel of truth Am. J. Clinical Nutrition, December 1, 2004; 80(6): 1459 - 1460. [Full Text] [PDF]
|
|
|
|
|
|
C. Gouedard, R. Barouki, and Y. Morel Induction of the Paraoxonase-1 Gene Expression by Resveratrol Arterioscler. Thromb. Vasc. Biol., December 1, 2004; 24(12): 2378 - 2383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Krotz, H.-Y. Sohn, and U. Pohl Reactive Oxygen Species: Players in the Platelet Game Arterioscler. Thromb. Vasc. Biol., November 1, 2004; 24(11): 1988 - 1996. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Kris-Etherton, A. H. Lichtenstein, B. V. Howard, D. Steinberg, J. L. Witztum, and for the Nutrition Committee of the American Heart Antioxidant Vitamin Supplements and Cardiovascular Disease Circulation, August 3, 2004; 110(5): 637 - 641. [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Levy, P. Friedenberg, R. Lotan, P. Ouyang, M. Tripputi, L. Higginson, F. R. Cobb, J.-C. Tardif, V. Bittner, and B. V. Howard The Effect of Vitamin Therapy on the Progression of Coronary Artery Atherosclerosis Varies by Haptoglobin Type in Postmenopausal Women Diabetes Care, April 1, 2004; 27(4): 925 - 930. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Anderson and J. F. Carlquist Genetic polymorphisms of hepatic lipase and cholesteryl ester transfer protein, intermediate phenotypes, and coronary risk: Do they add up yet? J. Am. Coll. Cardiol., June 4, 2003; 41(11): 1990 - 1993. [Full Text] [PDF]
|
|
|
|
|
|
B. F. Asztalos, M. Batista, K. V. Horvath, C. E. Cox, G. E. Dallal, J. S. Morse, G. B. Brown, and E. J. Schaefer Change in {alpha}1 HDL Concentration Predicts Progression in Coronary Artery Stenosis Arterioscler. Thromb. Vasc. Biol., May 1, 2003; 23(5): 847 - 852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Matthan, A. Giovanni, E. J. Schaefer, B. G. Brown, and A. H. Lichtenstein Impact of simvastatin, niacin, and/or antioxidants on cholesterol metabolism in CAD patients with low HDL J. Lipid Res., April 1, 2003; 44(4): 800 - 806. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||